AIM ImmunoTech Inc.
AIM XASE
$0.36
-0.03 (-8.33%)
▼
15-min delayed
Open
$0.36
High
$0.37
Low
$0.35
Volume
1.21M
Market Cap
$10.53M
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.0K | $-3,023,000 | $-0.69 |
| FY 2025 | $88.0K | $-13,958,000 | $-8.62 |
| Q3 2025 | $26.0K | $-3,284,000 | $1.57 |
| Q1 2025 | $16.0K | $-3,705,000 | $-0.05 |
Earnings & Analyst Ratings
Next Earnings:
Wed, Aug 12, 2026
Calendar →
TickerDaily Coverage
Why Is AIM ImmunoTech (AIM) Stock Up 54.7% Today?
Penny Stocks
Marcus Rivera · May 27, 2026
AIM ImmunoTech (AIM) stock ripped 54.7% higher to $0.368 on Wednesday after the biotech announced a...
Why Is AIM ImmunoTech (AIM) Stock Up 63.4% Today?
Penny Stocks
Marcus Rivera · May 18, 2026
AIM ImmunoTech (AIM) stock exploded 63.4% higher Monday, May 18, 2026, reaching $0.4089 on massive...
View All Coverage →
Get AIM Alerts
Stay ahead with breaking news, price alerts, and expert analysis on AIM ImmunoTech Inc..
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.